Clinical Trial Update: Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating sorafenib for hepatocellular carcinoma with microvascular invasion after radical resection has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Recurrence | Phase 3 | Status: TERMINATED